RightEye Clinical Case Study Highlights Risk of Long-Term Binocular Vision Issues Following Concussions

Monday, July 17, 2017 | Medical Studies


RightEye announced the publication of a new clinical case study published in the journal Translational Biomedicine demonstrating the long-term eye movement issues that can affect patients with concussion or other suspected brain injury. The paper, authored by RightEye co-founder and Chief Science Officer Dr. Melissa Hunfalvay, examines vision challenges following a patient’s suspected concussion and subsequent vision therapy. The findings indicate that head trauma can lead to binocular vision issues and validates the use of the RightEye system to assess these issues and monitor patient change over time in conjunction with and following vision therapy.

“Concussions and other brain injuries can have long-lasting effects on patients that are difficult to identify, and even harder to monitor for improvement over time,” Dr. Hunfalvay said in a company news release. “The results of our clinical case study indicate that RightEye is an effective method for identifying these challenges, monitoring improvement and even fostering better results with vision therapy training games.

The case study, published online and in the July edition of the journal, examined clinical assessments and the use of eye tracking technology to monitor patient change over time and after vision therapy. Following suspected head trauma, the patient used the RightEye system for testing oculomotor behavior, which indicated that all oculomotor metrics – including binocular coordination, depth perception and smooth pursuit – fell outside norms. Based on this information, the patient began twice-weekly vision therapy. After a year, she was tested again with the RightEye system, which showed marked improvement across all metrics. The clinical case study highlights the possible long-term effects of vision issues after a concussion, and also validates RightEye as a quantitative method for ongoing clinical analysis.

“We’re very excited to have our product and outcomes validated in this important clinical case study,” said Barbara Barclay, President of RightEye. “This means more cost-effective identification and better recovery for the more than three million Americans who suffer from mild brain injury each year.”

To learn more about RightEye, please visit them at Booth No. 5 at the American Academy of Neurology 2017 Sports Concussion Conference, July 14-16 in Jacksonville, Florida. More details are available at www.righteye.com, or in the online press kit at bitly.com/RightEyePress.


Comments

You must be logged in to leave a comment.